Back to Agenda
Session 8: Suppy Chain & Sample Management
Session Chair(s)
Joerg Garbe, PhD, MSc
IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland
Doaa Rady
Lot Release administration manager, Egyptian Drug Authority (EDA), Egypt
This Session will explore the global trend of using a Reliance-based waiver for in-country testing. Regulators will share their practical experiences with risk-based surveillance testing to replace import/registration testing. The goal of this session is to support regulators in the MENA region in optimising their testing systems to avoid waste of resources and ensure no delay of drug supply to patients.
Speaker(s)
Joerg Garbe, PhD, MSc
IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead, F. Hoffmann-La Roche Ltd, Switzerland
Introduction: Global Trends and Regional Perspective
Rutendo Kuwana, RPh
Team Lead, Incidents and Substandard/Falsified Medical Products, World Health Organization (WHO), Switzerland
WHO - Reliance for Sample Testing
Rania Elafifi
Regulatory Affairs Lead - Egypt, Roche, Egypt
Regional Perspective on In-Country Testing
Doaa Rady
Lot Release administration manager, Egyptian Drug Authority (EDA), Egypt
Practical Implementation of Risk-Based Strategies and Optimized Testing Systems in Egypt
Pavle Zelic
International Cooperation, European Integrations and Public Relations, Medicines and Medical Devices Agency of Serbia (ALIMS), Serbia
Risk-based Surveillance Testing in Serbia and How it Complements Anti-Counterfeit Activities in Serbia
Rana Malkawi
Drug Directorate Director, Jordan Food and Drug Administration (JFDA), Jordan
Panel Discussion with QandA, with the additional participation of:
Agnes Chan
Director, Therapeutic Products Branch, Health Sciences Authority, Singapore
Panel Discussion with QandA, with the additional participation of:
Have an account?